Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Internal Medicine›Condition·Updated Apr 17, 2026·v1

Diabetic Nephropathy

Diabetic nephropathy is a leading cause of ESRD, requiring a shift from simple glucose control to a multi-pillar cardiorenal-metabolic strategy. Management centers on RAAS inhibition, SGLT2 inhibitors, non-steroidal MRAs (Finerenone), and GLP-1 receptor agonists, alongside intensive blood pressure and lipid control.

High Evidence221 references·9,226 words·37 min read·v1
nephrologyendocrinologydiabeteschronic kidney diseasecardiorenal

Quick Reference

RxDrug of choiceACE inhibitor or ARB (Foundational) + SGLT2 inhibitor (e.g., Dapagliflozin 10 mg)
AltAlternativesFinerenone (ns-MRA), Semaglutide (GLP-1 RA), Pentoxifylline 400 mg TID (for advanced CKD)
⊘AvoidDual RAAS blockade (ACEi + ARB), SGLT2 inhibitors in patients with eGFR <20 mL/min/1.73m² (initiation)
DxTest of choiceUrinary albumin-to-creatinine ratio (UACR) and eGFR (Annual screening)
ScKey scoreELIXA risk score or KDIGO risk categories (eGFR + UACR)
→When to refereGFR <30 mL/min/1.73m², rapid eGFR decline (>5 mL/min/year), or suspected non-diabetic kidney disease
Manage diabetic nephropathy through a four-pillar pharmacological approach (RAASi, SGLT2i, ns-MRA, GLP-1RA) to reduce the high risk of ESRD and cardiovascular death.
Diabetic nephropathy (DN), increasingly referred to under the broader clinical umbrella of [[diabetic kidney disease]] (DKD), is a progressive microvascular complication of [[diabetes mellitus]] and the leading cause of end-stage renal disease (ESRD) worldwide. It is characterized by persistent albuminuria, a progressive decline in the [[estimated glomerular filtration rate]] (eGFR), and elevated arterial blood pressure. The management paradigm has recently shifted from simple glycemic and blood pressure control to a comprehensive cardiorenal-metabolic strategy. This approach utilizes four foundational pillars of therapy—[[ACE inhibitors]] or [[angiotensin receptor blockers]] (ARBs), SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (ns-MRAs), and GLP-1 receptor agonists—to mitigate the high residual risk of kidney failure and cardiovascular death. Early identification of high-risk phenotypes, including the increasingly recognized non-albuminuric variant, is essential for preserving long-term renal function.

Overview and Recommendations

Background

  • •Recognize diabetic nephropathy as a clinical syndrome arising from long-standing diabetes, traditionally defined by the progression from glomerular hyperfiltration to microalbuminuria (30–300 mg/day), overt macroalbuminuria (>300 mg/day), and eventually end-stage renal disease.
  • •Distinguish between the classic albuminuric phenotype and the non-albuminuric phenotype; the latter is increasingly common in and is characterized by a declining eGFR (<60 mL/min/1.73m²) without significant albuminuria, often reflecting tubulointerstitial or macrovascular aging rather than pure glomerular injury.
  • •Understand the Mogensen stages of progression, which begin with Stage 1 (Hyperfiltration, GFR >140 mL/min/1.73m²) and Stage 2 (Silent stage with structural changes like basement membrane thickening), before progressing to clinically detectable Stage 3 (Incipient nephropathy) and Stage 4 (Overt nephropathy).
  • •Identify the systemic nature of the disease through the lens of Metabolic Cardiovascular Renal Disease (Met-CVRD), which highlights the bidirectional relationship between the heart and kidneys mediated by chronic low-grade inflammation, mitochondrial dysfunction, and metabolic instability.
  • •Note the significant epidemiological burden, as approximately 30-40% of individuals with diabetes will develop chronic kidney disease, which serves as a potent multiplier for premature mortality and cardiovascular events.

Evaluation

  • •Screen all patients with type 2 diabetes at the time of diagnosis and patients with type 1 diabetes five years after diagnosis, using both the urinary albumin-to-creatinine ratio (UACR) and the (eGFR).
  • •Confirm the diagnosis of persistent albuminuria by obtaining at least two elevated UACR samples (≥30 mg/g) over a three-to-six-month period, as transient elevations can occur due to exercise, infection, or heart failure.
  • •Perform a comprehensive fundoscopic examination or optical coherence tomography (OCT) to screen for ; the presence of proliferative retinopathy or hard exudates is a strong clinical predictor of concurrent diabetic nephropathy and rapid eGFR decline.
  • •Assess for metabolic and anthropometric risk factors beyond BMI, specifically measuring the Visceral Fat Area (VFA) or calculating the Metabolic Score for Visceral Fat (METS-VF), as visceral adiposity is a more potent driver of renal decline than subcutaneous fat.
  • •Evaluate glycemic stability by reviewing HbA1c variability and continuous glucose monitoring (CGM) metrics, specifically the Time in Range (TIR; 70–180 mg/dL), as high glucose fluctuations trigger repetitive bouts of oxidative stress that damage the renal microvasculature.
  • •Order serum uric acid (SUA) levels, as even high-normal levels are independently associated with early impaired kidney function and may necessitate more aggressive monitoring.
  • •Suspect non-diabetic kidney disease (NDKD) if the patient presents with "red flags" such as the absence of retinopathy (especially in type 1 diabetes), sudden onset of nephrotic syndrome, active urinary sediment (dysmorphic red cells or casts), or a rapid decline in eGFR (>5 mL/min/1.73m²/year).
  • •Utilize the ELIXA risk score—incorporating age, BMI, HbA1c, systolic blood pressure, lipids, smoking status, and retinopathy—to categorize patients into low, moderate, high, or very high-risk groups for cardiorenal outcomes.
  • •Measure B-type natriuretic peptide (BNP) levels; high-normal levels (>14.5 pg/mL) can predict eGFR decline independent of baseline albuminuria and provide incremental prognostic value.
  • •Consider a renal biopsy only when clinical features are atypical for diabetic nephropathy to rule out primary glomerulonephritides like or , which may require immunosuppressive therapy.

Management

  • •Initiate foundational therapy with the maximum tolerated dose of an (e.g., Lisinopril 10–40 mg daily) or an (e.g., Losartan 50–100 mg daily) for all patients with hypertension and albuminuria to reduce intraglomerular pressure.
  • •Administer an SGLT2 inhibitor (e.g., Dapagliflozin 10 mg daily or Empagliflozin 10 mg daily) as first-line therapy for patients with an eGFR ≥20–25 mL/min/1.73m², regardless of glycemic control, to provide potent nephroprotection and reduce the risk of heart failure.
  • •Add a non-steroidal mineralocorticoid receptor antagonist (ns-MRA), specifically Finerenone 10 mg or 20 mg daily, for patients with persistent albuminuria (UACR ≥30 mg/g) despite optimized ACEi/ARB and SGLT2i therapy, provided serum potassium is ≤4.8 mEq/L.
  • •Incorporate a GLP-1 receptor agonist (e.g., Semaglutide 1 mg weekly SC) for patients with high cardiovascular risk or persistent albuminuria, as these agents significantly reduce major kidney events and all-cause mortality.
  • •Target a blood pressure of <130/80 mmHg for most patients, though an intensive target of <120 mmHg may be considered if it can be achieved without significant adverse effects like acute kidney injury or hyperkalemia.
  • •Optimize lipid management using high-intensity (e.g., Atorvastatin 40–80 mg daily) to achieve an LDL-C target of <55 mg/dL (1.4 mmol/L), given the extreme cardiovascular risk associated with diabetic kidney disease.
  • •Monitor serum potassium closely, especially when combining RAAS inhibitors and Finerenone; use potassium binders if necessary to maintain levels <5.0 mmol/L and avoid the premature discontinuation of life-saving nephroprotective agents.
  • •Implement nutritional interventions focused on a high Oxidative Balance Score (OBS), encouraging a diet rich in antioxidants (e.g., Mediterranean or DASH diet) and smoking cessation to reduce systemic oxidative stress.
  • •Avoid the use of dual RAAS blockade (combining an ACEi and an ARB) due to the significantly increased risk of hyperkalemia and acute kidney injury without additional benefit.
  • •Refer to a nephrologist when the eGFR falls below 30 mL/min/1.73m², when there is a rapid decline in renal function, or when the etiology of the kidney disease is uncertain.
  • •Prepare for renal replacement therapy (RRT) when eGFR approaches <15–20 mL/min/1.73m², prioritizing kidney transplantation or integrated endocrinology-transplant care to optimize post-transplant metabolic outcomes.
  • •Utilize Continuous Glucose Monitoring (CGM) for patients on dialysis to assess glycemic control, as HbA1c becomes increasingly unreliable in the setting of advanced uremia and altered red blood cell turnover.

Board Review — High Yield

  • •Kimmelstiel-Wilson nodules — Pathognomonic histopathological finding of intercapillary glomerulosclerosis in diabetic nephropathy.
  • •Hyperfiltration — The earliest functional change in DN, driven by afferent arteriolar dilation (SGLT2-mediated) and efferent constriction (RAAS-mediated).
  • •Non-albuminuric DKD — A phenotype where eGFR declines without significant proteinuria, more common in Type 2 Diabetes and associated with macrovascular disease.
  • •Finerenone — A non-steroidal MRA that provides anti-inflammatory/anti-fibrotic benefits with less hyperkalemia than spironolactone.
  • •Eye-Kidney Axis — The high correlation between diabetic retinopathy and nephropathy; retinopathy is nearly always present in Type 1 diabetics with DN.
  • •Metabolic Memory — The phenomenon where early glycemic control provides long-term protection against complications, mediated by the NAD+-SIRT3 axis.
  • •SGLT2i Mechanism — Restores tubuloglomerular feedback by increasing sodium delivery to the macula densa, leading to afferent arteriolar vasoconstriction.

Deep Dive — Evidence Details

References

  1. [1]

    Heerspink HJL, List J, Perkovic V. “New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.” Diabetes, obesity & metabolism (2018). PMID: 30294954 ↗

    L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification
  2. [2]

    Bansal A, Chonchol M. “Metabolic dysfunction-associated kidney disease: pathogenesis and clinical manifestations.” Kidney international (2025). PMID: 40379048 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  3. [3]

    Eckardt KU, Coresh J, Devuyst O et al.. “Evolving importance of kidney disease: from subspecialty to global health burden.” Lancet (London, England) (2013). PMID: 23727165 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  4. [4]

    Pozzilli P, Messina MV, Roden M. “Metabolic Cardiovascular Renal Disease (Met-CVRD): A New Nomenclature.” Diabetes/metabolism research and reviews (2025). PMID: 40888594 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  5. [5]

    Gao X, Wei J, Hao T et al.. “Dysgonomonas mossii Strain Shenzhen WH 0221, a New Member of the Genus Dysgonomonas Isolated from the Blood of a Patient with Diabetic Nephropathy, Exhibits Multiple Antibiotic Resistance.” Microbiology spectrum (2022). PMID: 35913210 ↗

    L4CASE_REPORTCited in: Definition, Synonyms, and Classification
  6. [6]

    Kanasaki K, Ueki K, Nangaku M. “Diabetic kidney disease: the kidney disease relevant to individuals with diabetes.” Clinical and experimental nephrology (2024). PMID: 39031296 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  7. [7]

    Kalra PA. “Renal specific secondary hypertension.” Journal of renal care (2007). PMID: 17695554 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  8. [8]

    Tuncer O, Köster I, Meyer I et al.. “[Development and internal validation of case definitions for kidney disease in patients with diabetes based on routine data of statutory health insurance].” Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) (2025). PMID: 40451195 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  9. [9]

    Icks A, Rathmann W, Haastert B et al.. “[Quality of care and extent of complications in a population-based sample of patients with type 2 diabetes mellitus. The KORA Survey 2000].” Deutsche medizinische Wochenschrift (1946) (2006). PMID: 16418944 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  10. [10]

    Basu M, Ghosh S. “Chronic Kidney Disease with Risk Factor Diabetes: Need for Change in Nomenclature Reflecting Heterogeneity of Kidney Disease in Diabetes.” The Journal of the Association of Physicians of India (2026). PMID: 41818088 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  11. [11]

    Ding L, Li Z, Xia Y et al.. “Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review.” Renal failure (2026). PMID: 41845912 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors, Diagnosis and Workup
  12. [12]

    Guo S, Zhao X. “Lipoprotein-associated phospholipase A2 and complications of diabetes mellitus: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41767386 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors, Supportive Care and Complication Management
  13. [13]

    Wu C, Qin H, Wei M et al.. “Association between glycated hemoglobin variability and risk of diabetic kidney disease and diabetic retinopathy in diabetic patients: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41694560 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Supportive Care and Complication Management
  14. [14]

    Guo Y, Gao W, Li S et al.. “Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in the treatment of diabetic kidney disease: a meta-analysis.” Frontiers in endocrinology (2025). PMID: 41675637 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes
  15. [15]

    Zhao J, Zhao L. “A meta-analysis of serum uric acid and diabetic nephropathy risk in type 2 diabetes.” Frontiers in endocrinology (2025). PMID: 41669246 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors
  16. [16]

    Jiang W, Wang J, Li J et al.. “Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial.” Frontiers in endocrinology (2026). PMID: 41928879 ↗

    L1bRCTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Clinical Features and Variants, Diagnosis and Workup, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations
  17. [17]

    Yang Y, Tan H, Xiao Z et al.. “Landscape of diabetic kidney disease drug clinical trials in China (2013-2023): global implications for innovation and policy.” Renal failure (2026). PMID: 41724716 ↗

    L2bTRIAL_NONRANDOMCited in: Epidemiology and Risk Factors
  18. [18]

    Weingold R, Filippatos G, Anker SD et al.. “Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY.” Journal of diabetes and its complications (2026). PMID: 41679125 ↗

    L1bRCTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Clinical Features and Variants, Supportive Care and Complication Management, Landmark Trials and Key Evidence, Special Populations, Guidelines and Resources
  19. [19]

    Shi J, Zhao D, Wang J et al.. “Sex-specific and BMI-specific associations between visceral fat and diabetic kidney disease in patients with diabetes: a large-scale multicentre prospective cohort study.” The lancet. Diabetes & endocrinology (2026). PMID: 41991218 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Diagnosis and Workup, Special Populations
  20. [20]

    Yang R, Liu Y, Li J. “Assessing the association of FIB-4 index with diabetic kidney disease in patients with diabetes mellitus: a cross-sectional and retrospective study utilizing NHANES and clinical data.” Frontiers in endocrinology (2026). PMID: 41907551 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Special Populations
  21. [21]

    Hu J, Ge T, Zhu Q et al.. “Association between the oxidative balance score and risk of microvascular complications in type 2 diabetes: A prospective UK biobank cohort study.” Diabetes, obesity & metabolism (2026). PMID: 41705623 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Pathophysiology, Supportive Care and Complication Management, Special Populations
  22. [22]

    Deng L, Li X, Ran J et al.. “Acute-to-chronic glycemic ratio: a promising biomarker for prognosis of diabetic foot ulcers in a multi-center cohort study.” Diabetology & metabolic syndrome (2026). PMID: 41680933 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors
  23. [23]

    Deng Z, Yang J, Zhou H. “Development and validation of a model that predicts the risk of diabetic kidney disease in type 2 diabetes mellitus patients: a retrospective study.” Frontiers in endocrinology (2025). PMID: 41607464 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors
  24. [24]

    Chow EWK, Fan Y, Wu H et al.. “Age-specific associations between blood pressure and cardiovascular disease, kidney disease, and death among individuals with type 2 diabetes: a population-based cohort study.” Cardiovascular diabetology (2026). PMID: 41606584 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Supportive Care and Complication Management, Prognosis and Long-term Outcomes
  25. [25]

    Sun T, Li S, Liu J. “Association between the total bilirubin to prothrombin time ratio index and diabetic retinopathy, nephropathy, peripheral neuropathy, and foot disease: a retrospective study and risk prediction model construction.” Frontiers in endocrinology (2025). PMID: 41601923 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Supportive Care and Complication Management, Prognosis and Long-term Outcomes
  26. [26]

    Li X, Zhang X. “Association between serum uric acid and urinary uric acid excretion indicators and early impaired kidney function in newly diagnosed T2DM patients with normal serum uric acid levels: a retrospective study.” PeerJ (2026). PMID: 41777687 ↗

    L2bTRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Diagnosis and Workup, Special Populations
  27. [27]

    Yang L, Zhou B, Deng R. “Relationship between glycemic variability and renal function progression in patients with diabetic nephropathy: A retrospective cohort study.” Medicine (2026). PMID: 41630253 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes
  28. [28]

    Sarker J, Abdelaziz AI, Crook J et al.. “Cost-Effectiveness Analysis of Artificial Intelligence-Driven Risk Stratification in Patients With Diabetic Kidney Disease in the US Veterans Population.” Kidney medicine (2026). PMID: 41993683 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Guidelines and Resources
  29. [29]

    Xu M, Yan H, Gu T et al.. “Visceral fat score predicts diabetic kidney disease: analysis of 20 years of U.S. NHANES data.” Renal failure (2026). PMID: 41947490 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Clinical Features and Variants, Diagnosis and Workup, Special Populations
  30. [30]

    Hirakawa Y, Sugawara Y, Nangaku M. “Prevalence of diagnostic Mendelian kidney disease variants in type 2 diabetes with and without diabetic kidney disease.” Journal of diabetes investigation (2026). PMID: 41923384 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  31. [31]

    Groothof D, Shehab NBN, Post A et al.. “SGLT2 Inhibitors, Muscle Loss, and Creatinine-Based Estimated GFR: An Integrative Conceptual Review of Renoprotection.” Kidney medicine (2026). PMID: 41908618 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
  32. [32]

    Pantis C, Vesa CM, Ghitea TC et al.. “Diabetes Duration Is Associated with Declining Kidney Function: eGFR and CKD Burden Across Duration.” Journal of clinical medicine (2026). PMID: 41899160 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  33. [33]

    Xing Y, Yang X, Zhao Q. “The association between family history of hypertension and diabetic kidney disease in patients with diabetes: a cross-sectional study.” Frontiers in endocrinology (2026). PMID: 41877930 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Diagnosis and Workup, Special Populations
  34. [34]

    Ozdede M, Pavlou P, Avataneo M et al.. “Impact of Body Mass Index Variability on Kidney Disease Progression in a Large Type 1 Diabetes Cohort.” Diabetes/metabolism research and reviews (2026). PMID: 41854625 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Diagnosis and Workup, Prognosis and Long-term Outcomes
  35. [35]

    Lohia S, Zoidakis J, Vlahou A et al.. “Integrative Analysis on the Urinary Proteome of Diabetic Kidney Disease, with an Emphasis on Extracellular Matrix Proteins.” International journal of molecular sciences (2026). PMID: 41828502 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  36. [36]

    Li Y, Wang Z, Ma Y et al.. “The nonlinear association between Body Roundness Index and left ventricular diastolic dysfunction in type 2 diabetes.” Frontiers in endocrinology (2026). PMID: 41821734 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Special Populations
  37. [37]

    Nobayashi H, Satoh M, Hirose T et al.. “Comparison of SGLT2 Inhibitors for New-Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function.” Diabetes, obesity & metabolism (2026). PMID: 41804189 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors
  38. [38]

    Cobuz C, Ungureanu-Iuga M, Cobuz M. “An integrative analysis of cardiac autonomic neuropathy and nephropathy risk assessed with SUDOSCAN in individuals with type 2 diabetes.” Frontiers in endocrinology (2026). PMID: 41767395 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors
  39. [39]

    Lim MY, Lian W, Phua HP et al.. “Visit-to-visit HbA1c variability, risk of all-cause mortality and diabetes-related vascular complications among adult individuals with type 2 diabetes mellitus.” Diabetes, obesity & metabolism (2026). PMID: 41749305 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors
  40. [40]

    Yang Y, Liu Z, Huang Y et al.. “Associations of time in tight range, time in range, and glycated hemoglobin with albuminuria and diabetic kidney disease in adult type 2 diabetes: a cross-sectional study.” BMC endocrine disorders (2026). PMID: 41749212 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Clinical Features and Variants
  41. [41]

    Zhang J, Li Y, Dai B et al.. “The bidirectional association between obstructive sleep apnea and diabetic kidney disease: systematic review and meta-analysis.” Frontiers in endocrinology (2025). PMID: 41367908 ↗

    L2aSR_OBSCited in: Etiology and Triggering Factors
  42. [42]

    Li N, Sun J, Li H et al.. “Drug-gene interactions and the risk of diabetic microvascular complications: A population-based cohort study.” Diabetes, obesity & metabolism (2026). PMID: 41582657 ↗

    L2bCOHORTCited in: Etiology and Triggering Factors, Supportive Care and Complication Management
  43. [43]

    Brillinger J, Filliter C, Salmasi S et al.. “Long-acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population-based cohort study.” Diabetes, obesity & metabolism (2026). PMID: 41521903 ↗

    L2bCOHORTCited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes
  44. [44]

    Oh R, Kim S, Cho SH et al.. “Elevated triglyceride-glucose index is associated with increased risk of chronic kidney disease and end-stage renal disease in type 1 diabetes: Nationwide cohort study.” Diabetes, obesity & metabolism (2026). PMID: 41500979 ↗

    L2bCOHORTCited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes
  45. [45]

    Li R, Xu K, Zhu K et al.. “Healthful dietary patterns and risks of microvascular complications among individuals with type 2 diabetes: a prospective cohort study.” The American journal of clinical nutrition (2026). PMID: 41298211 ↗

    L2bCOHORTCited in: Etiology and Triggering Factors, Supportive Care and Complication Management
  46. [46]

    Chrysostomou C, Faustini F, Segelmark M et al.. “A national cohort study examined the risk of severe infection and infection-related mortality in patients with chronic kidney disease with lupus nephritis in comparison to other chronic kidney disease etiologies.” Kidney international (2026). PMID: 41276017 ↗

    L2bCOHORTCited in: Etiology and Triggering Factors, Differential Diagnosis
  47. [47]

    Nicholas SB, Nobakht N, Alicic RZ. “Therapeutic Considerations in Preventing Chronic Kidney Disease.” Annual review of medicine (2026). PMID: 41270289 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Supportive Care and Complication Management
  48. [48]

    Rani P, Nagaraju SP, Swaminathan SM et al.. “Prevalence and Predictors of Rapid Estimated Glomerular Filtration Rate Decline in Patients with Non-albuminuric Diabetic Kidney Disease: A Single-centre Retrospective Cohort Study.” The Nigerian postgraduate medical journal (2026). PMID: 41479184 ↗

    L2bCOHORTCited in: Etiology and Triggering Factors, Clinical Features and Variants
  49. [49]

    Izarra A, Bermúdez-López M, Valdivielso JM et al.. “Baseline and 4-year associations between prediabetes and kidney impairment: Insights from the ILERVAS cohort.” Diabetes, obesity & metabolism (2026). PMID: 41705635 ↗

    L5OTHERCited in: Etiology and Triggering Factors, Clinical Features and Variants, Guidelines and Resources
  50. [50]

    Hu Q, Chen L, Xing L et al.. “Association of remnant cholesterol with cardiovascular events and mortality in biopsy-proven diabetic kidney disease.” Frontiers in endocrinology (2026). PMID: 41685232 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  51. [51]

    Tian Q, Liu Y, Cao Q et al.. “The predictive potential of surrogate indicators of insulin resistance for type 2 diabetic kidney disease.” Frontiers in endocrinology (2026). PMID: 41675566 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  52. [52]

    Qin JL, Zhao J, Chen YL et al.. “Metabolic syndrome and diabetic kidney disease: a consistent dose-response association validated in an independent clinical cohort.” Frontiers in endocrinology (2025). PMID: 41659341 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  53. [53]

    Naik AS, Alakwaa FM, Nair V et al.. “Metabolic surgery mitigates early kidney injury in obese youth with diabetes by suppressing mTORC1/JAK/STAT signaling.” The Journal of clinical investigation (2026). PMID: 41665972 ↗

    L2bTRIAL_NONRANDOMCited in: Pathophysiology
  54. [54]

    Wei T, Huang J, Wan B et al.. “Unveiling the Therapeutic Potential of Suyin Detoxification Prescription in Diabetic Nephropathy: A Comprehensive Study Integrating Clinical Efficacy, Network Pharmacology, and Molecular Mechanisms.” Journal of diabetes research (2025). PMID: 41497482 ↗

    L1bRCTCited in: Pathophysiology
  55. [55]

    Zhang Y, Wang Y, Qiao Y et al.. “Targeting the NAD+-SIRT3 axis to mitigate metabolic memory in diabetic kidney disease.” Renal failure (2026). PMID: 41991506 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  56. [56]

    Cao W, Cao G, Meng Q et al.. “Integrative Insights Into Mitochondrial Dysfunction and Organelle Crosstalk in Diabetic Kidney Disease.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 41863504 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  57. [57]

    Pandey A, Badruddeen, Akhtar J et al.. “Impact of angiopoietin-like 4 (ANGPTL4) protein and O-linked β-N-acetylglucosamine(O-GlcNAc) in diabetic nephropathy.” Diabetes research and clinical practice (2026). PMID: 41833781 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  58. [58]

    Shao N, Wang J, Liu J et al.. “Mitochondrial Dynamics in Diabetic Kidney Disease: Underlying Mechanisms and Novel Therapeutics.” International journal of molecular sciences (2026). PMID: 41828648 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  59. [59]

    He M, Wang Z, Miao Z et al.. “Post‑translational modifications in diabetic kidney disease (Review).” International journal of molecular medicine (2026). PMID: 41685570 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  60. [60]

    Zhang RM, Caramori ML. “Inflammation and Diabetic Kidney Disease.” International journal of molecular sciences (2026). PMID: 41596736 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  61. [61]

    Verma A, Upadhyay A. “Diabetic kidney disease, biomarkers, and finerenone.” Diabetes, obesity & metabolism (2026). PMID: 41555617 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology, Supportive Care and Complication Management
  62. [62]

    Yang K, Fang Y, He J et al.. “Adipokine networks in diabetic kidney disease: mechanistic insights and therapeutic implications.” Lipids in health and disease (2026). PMID: 41519764 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  63. [63]

    Xu Y, Wu X, Ge M et al.. “Soluble guanylate cyclase modulators-a novel therapeutic approach for diabetic kidney disease.” Renal failure (2025). PMID: 41485909 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  64. [64]

    Lee A. “Mouse Models of Diabetic Complications: Dissecting Molecular Mechanisms of Disease Progression.” Frontiers in bioscience (Landmark edition) (2026). PMID: 41914292 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  65. [65]

    Varda L, Vreča N, Ekart R et al.. “Diabetic Kidney Disease: From Pathophysiology to Treatment Perspectives.” Kidney & blood pressure research (2026). PMID: 41632731 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  66. [66]

    Husain-Syed F, Yuecel G, Daschner C et al.. “Therapeutic Advances in Diabetic Kidney Disease: 30 Years of Evidence and the Rise of the "Fantastic Four" in Nephrology.” Cardiorenal medicine (2026). PMID: 41528949 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  67. [67]

    Gong D, Chen X, Dong Z et al.. “Resveratrol inhibits renal ischemia and reperfusion injury in diabetes via reducing oxidative stress, inflammation, and apoptosis.” Renal failure (2026). PMID: 41958068 ↗

    L5OTHERCited in: Pathophysiology, Supportive Care and Complication Management
  68. [68]

    Ni B, Yang Y, Yu B et al.. “Hirsutine mitigates high glucose-induced cell injury via autophagy activation and NRF2/GPX4-mediated ferroptosis inhibition.” Renal failure (2026). PMID: 41913060 ↗

    L5OTHERCited in: Pathophysiology
  69. [69]

    Wang H, Guo J, Wang Q et al.. “ADAMTS13 ameliorates diabetic nephropathy by Nrf2/GPX4/eNOS signaling pathway.” Renal failure (2026). PMID: 41912450 ↗

    L5OTHERCited in: Pathophysiology
  70. [70]

    Xia W, Wang M, Gao Y et al.. “Unveiling the TrkA-p35/CDK5 axis: a novel therapeutic target in diabetic kidney disease.” Frontiers in endocrinology (2026). PMID: 41907549 ↗

    L5OTHERCited in: Pathophysiology
  71. [71]

    Wu Y, Fan L, You H et al.. “Qigui didang decoction alleviates renal injury in a diabetic kidney disease model with metabolic memory features: association with ferroptosis and the SIRT1/Nrf2 pathway.” Pharmaceutical biology (2026). PMID: 41874449 ↗

    L5OTHERCited in: Pathophysiology
  72. [72]

    Li Y, Rao J, Lai W et al.. “IL-15 Links Muscle-Kidney Crosstalk to Preserving Podocyte Mitochondrial Fusion and Attenuating Diabetic Nephropathy.” Journal of cachexia, sarcopenia and muscle (2026). PMID: 41846397 ↗

    L5OTHERCited in: Pathophysiology
  73. [73]

    Li W, Bai R, Gao X et al.. “MR Elastography in Diabetic Rats: Assessing Glomerular Hyperfiltration, Dapagliflozin Therapy Response, and Early Diabetic Nephropathy.” Journal of magnetic resonance imaging : JMRI (2026). PMID: 41840723 ↗

    L5OTHERCited in: Pathophysiology
  74. [74]

    Lin WR, Huang TS, Chang HH et al.. “Kidney Effectiveness and Safety of Adding Spironolactone in Patients With Type 2 Diabetes Receiving Renin-Angiotensin System Inhibitors Therapy.” Clinical and translational science (2026). PMID: 41839821 ↗

    L5OTHERCited in: Pathophysiology, Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations
  75. [75]

    Aguilar-Cartes M, Opazo-Ríos L, Droguett A et al.. “SOCS1 Mimetic Peptide Enhances Empagliflozin Improvement on Kidney Damage in the Type 2 Diabetes Mouse Model BTBR ob/ob.” International journal of molecular sciences (2026). PMID: 41828692 ↗

    L5OTHERCited in: Pathophysiology
  76. [76]

    Jelinčić Korčulanin M, Racetin A, Pavlović N et al.. “Connexin 43 and Pannexin 1 in Renal Cell Populations in Diabetic Kidney Disease.” International journal of molecular sciences (2026). PMID: 41828379 ↗

    L5OTHERCited in: Pathophysiology, Special Populations
  77. [77]

    Hou Q, Huang G, Kan S et al.. “Acarbose ameliorates podocyte injury and glomerular lesions in diabetic nephropathy through USP46 activation.” Science translational medicine (2026). PMID: 41811985 ↗

    L5OTHERCited in: Pathophysiology, Clinical Features and Variants
  78. [78]

    Jiang Y, Chang J, Guo Y et al.. “TangShenWeiNing formula alleviates diabetic kidney disease by inhibiting ferroptosis via AMPK pathway in renal tubular epithelial cells.” Frontiers in endocrinology (2026). PMID: 41767403 ↗

    L5OTHERCited in: Pathophysiology
  79. [79]

    Novaes AS, Felizardo RJF, Camara NOS et al.. “Extracellular Vesicles Facilitate the Crosstalk Between High Glucose-Stimulated Mesangial Cells and Healthy Podocytes to Mediate Injury Responses.” International journal of molecular sciences (2026). PMID: 41752063 ↗

    L5OTHERCited in: Pathophysiology
  80. [80]

    Liu S, Xie K, Zhao H et al.. “Aflatoxin B1 accelerates diabetic nephropathy progression via ITGA11/LTBP1-dependent oxidative and fibrotic pathways: Evidence from multi-omics and molecular simulations.” Chemico-biological interactions (2026). PMID: 41722833 ↗

    L5OTHERCited in: Pathophysiology
  81. [81]

    Vatanparast RG, Aliyari M, Yazdi MP et al.. “Calebin A mitigates oxidative stress and inflammation in diabetic nephropathy via Nrf2/HO-1 and NF-κB signaling pathways.” Journal of diabetes investigation (2026). PMID: 41714879 ↗

    L5OTHERCited in: Pathophysiology
  82. [82]

    AbdelMagid AM, Kamel AM, Farid SF. “Beyond Monotherapy: The Superior Efficacy of Combined GLP-1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta-Analysis.” Pharmacotherapy (2026). PMID: 41947610 ↗

    L2aSR_OBSCited in: Clinical Features and Variants, Diagnosis and Workup
  83. [83]

    Passanisi S, Piona C, Mancioppi V et al.. “Optimal age, duration of diabetes and frequency of screening for diabetic nephropathy in children and youths with type 1 Diabetes: A systematic review.” Diabetes research and clinical practice (2026). PMID: 41371346 ↗

    L2aSR_OBSCited in: Clinical Features and Variants
  84. [84]

    Heerspink HJL, Birkenfeld AL, Cherney DZI et al.. “Finerenone in Type 1 Diabetes and Chronic Kidney Disease.” The New England journal of medicine (2026). PMID: 41780000 ↗

    L1bRCTCited in: Clinical Features and Variants, Diagnosis and Workup, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations
  85. [85]

    Murakoshi M, Kamei N, Tanaka M et al.. “High-normal levels of B-type natriuretic peptide are associated with chronic kidney disease progression independent of albuminuria in individuals with diabetes: an observational cohort study.” Diabetes research and clinical practice (2026). PMID: 41747771 ↗

    L2bCOHORTCited in: Clinical Features and Variants, Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations
  86. [86]

    Makino H, Kasahara M, Takashima R et al.. “Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double-blind, placebo-controlled trial.” Diabetes, obesity & metabolism (2026). PMID: 41582689 ↗

    L1bRCTCited in: Clinical Features and Variants
  87. [87]

    Mejía-Rodríguez O, Ávila-Díaz M, Prado-Uribe C et al.. “Short- and Middle-Term Nephroprotective and Cardioprotective Effects of Pentoxifylline in Patients with Diabetic Nephropathy: A Randomized Controlled Trial.” Medical sciences (Basel, Switzerland) (2026). PMID: 41562916 ↗

    L1bRCTCited in: Clinical Features and Variants, Guidelines and Resources
  88. [88]

    Munoz Mendoza J, Weir MR, Anker SD et al.. “Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.” Clinical journal of the American Society of Nephrology : CJASN (2026). PMID: 41533467 ↗

    L1bRCTCited in: Clinical Features and Variants, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence
  89. [89]

    Tanaka A, Vaduganathan M, Imai T et al.. “Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR).” Cardiovascular diabetology (2025). PMID: 41351003 ↗

    L1bRCTCited in: Clinical Features and Variants, Prognosis and Long-term Outcomes
  90. [90]

    Mottl A, Scott C, Green JB et al.. “Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.” Journal of the American Society of Nephrology : JASN (2026). PMID: 41196655 ↗

    L1bRCTCited in: Clinical Features and Variants
  91. [91]

    Arici M, Ates K, Yildiz A et al.. “Diabetes and chronic kidney disease in Turkey (DIAKIT): a cross-sectional cohort study.” BMC nephrology (2025). PMID: 41331919 ↗

    L2bCOHORTCited in: Clinical Features and Variants
  92. [92]

    Katayama S, Anker SD, Zhu D et al.. “Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function.” Journal of diabetes and its complications (2026). PMID: 41289823 ↗

    L1bRCTCited in: Clinical Features and Variants, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence
  93. [93]

    Chen K, Shao W, Zhang H. “Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease.” Medicine (2026). PMID: 41578591 ↗

    L2aSR_OBSCited in: Clinical Features and Variants, Prognosis and Long-term Outcomes
  94. [94]

    Meng L, Li Z, Xu L et al.. “Emerging technologies for early risk stratification and precision management of diabetic kidney disease: a multimodal framework integrating digital phenotypes and clinical biomarkers.” Frontiers in endocrinology (2025). PMID: 41585789 ↗

    L5REVIEW_NARRATIVECited in: Clinical Features and Variants
  95. [95]

    Motawi TK, Sabry D, Ahmed NM et al.. “Association of GAS6, AXL, and GAS6-AS lncRNAs with nephropathy in Egyptian patients with type 2 diabetes mellitus: a case-control observational study.” Nutrition & diabetes (2025). PMID: 41233312 ↗

    L3bCASE_CONTROLCited in: Clinical Features and Variants
  96. [96]

    Acharya A, Kotakala CMK, Kodanda Ramu B et al.. “Assessing Renoprotective Effects of Empagliflozin and Telmisartan Combination Therapy in Non-albuminuric Diabetic Nephropathy: A Retrospective Cohort Study.” Cureus (2025). PMID: 41625819 ↗

    L2bCOHORTCited in: Clinical Features and Variants
  97. [97]

    Ahmed RM, Soliman AR, Mohammed A. “Vonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism.” Scientific reports (2025). PMID: 41271916 ↗

    L1bRCTCited in: Clinical Features and Variants
  98. [98]

    Nugroho P, Lydia A, Soewondo P et al.. “Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial.” Annals of medicine (2025). PMID: 41145267 ↗

    L1bRCTCited in: Clinical Features and Variants
  99. [99]

    Kaygusuz Y, Özbek DA, Erdut A et al.. “Urinary Biomarker Profiles Define Divergent Pathways in Albuminuric and Non-Albuminuric Diabetic Kidney Disease.” Kidney diseases (Basel, Switzerland) (2026). PMID: 41938379 ↗

    L5OTHERCited in: Clinical Features and Variants
  100. [100]

    González-Luis A, Siverio-Morales O, Hernández-Carballo C et al.. “Inflammatory markers associated with albuminuria and early atherosclerosis in type 2 diabetic kidney disease: a cross-sectional study.” Frontiers in endocrinology (2026). PMID: 41837147 ↗

    L5OTHERCited in: Clinical Features and Variants, Special Populations
  101. [101]

    Wang J, Yu L, Yin J et al.. “The association between low hemoglobin-to-red blood cell distribution width ratio and macroalbuminuria in diabetic kidney disease: evidence from NHANES and an external validation cohort.” Renal failure (2026). PMID: 41833328 ↗

    L5OTHERCited in: Clinical Features and Variants, Special Populations
  102. [102]

    Zafar A, Scarlata C, Jaleel N. “Chronic kidney disease in type 2 diabetes in UK primary care: Testing frequency, coding accuracy and clinical inertia.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41677011 ↗

    L5OTHERCited in: Clinical Features and Variants
  103. [103]

    Su J, Su J, Wang W et al.. “Low HDL cholesterol is associated with elevated TNFR1 and TNFR2 levels in early diabetic kidney disease.” Frontiers in endocrinology (2026). PMID: 41658514 ↗

    L5OTHERCited in: Clinical Features and Variants
  104. [104]

    Cheng YW, Kao YW, Chen SW et al.. “Effect of SGLT2 inhibitors versus DPP4 inhibitors on major adverse kidney events in diabetic people with varied kidney function decline.” Frontiers in endocrinology (2025). PMID: 41625233 ↗

    L5OTHERCited in: Clinical Features and Variants
  105. [105]

    Bahari H, Asadi Z. “Effects of Curcumin/Turmeric Supplementation on Kidney Function in Individuals With Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Endocrinology, diabetes & metabolism (2026). PMID: 41761990 ↗

    L1aSR_MA_RCTCited in: Diagnosis and Workup
  106. [106]

    Wang Y, Liu X, Xiao Z. “The diagnostic value of immune-inflammatory markers for diabetic kidney disease in type 2 diabetic patients: a meta-analysis.” Frontiers in endocrinology (2026). PMID: 41958879 ↗

    L2aSR_OBSCited in: Diagnosis and Workup
  107. [107]

    Tang Y, Li Z, Jia Z. “Systematic review of ocular and circulatory cytokines linking diabetic retinopathy to kidney disease.” Frontiers in endocrinology (2026). PMID: 41890176 ↗

    L2aSR_OBSCited in: Diagnosis and Workup, Supportive Care and Complication Management
  108. [108]

    Dai B, Chen Y, Xiao Y et al.. “Efficacy and safety of Jinlida granules as an adjuvant treatment for diabetic nephropathy: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41767388 ↗

    L2aSR_OBSCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes
  109. [109]

    Goumboundi IA, Afrifa J, Ephraim RKD. “Association Between Monocyte-to-High-Density Lipoprotein Ratio and Diabetic Nephropathy: A Systematic Review and Meta-Analysis.” BioMed research international (2026). PMID: 41903155 ↗

    L2aSR_OBSCited in: Diagnosis and Workup
  110. [110]

    Hong SH, Lee H, Lee SY et al.. “Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study.” BMJ open (2026). PMID: 41856597 ↗

    L2bCOHORTCited in: Diagnosis and Workup, Special Populations
  111. [111]

    Yu L, Zhang Y, Sun C et al.. “Diabetic retinopathy severity is associated with renal function deterioration in patients with diabetic kidney disease: a retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 41837122 ↗

    L2bCOHORTCited in: Diagnosis and Workup, Supportive Care and Complication Management, Special Populations
  112. [112]

    Sabir S, Shahzad M, Malik UI et al.. “Effect of Mesenchymal Stem Cell Infusion in Stage II-IV Diabetic Nephropathy.” Journal of the College of Physicians and Surgeons--Pakistan : JCPSP (2026). PMID: 41792063 ↗

    L1bRCTCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations
  113. [113]

    Ramadurgum P, Sharma K, Pinon A et al.. “GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.” Current cardiology reports (2026). PMID: 41880122 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Supportive Care and Complication Management
  114. [114]

    Guo Y, Feng Y, Wu H et al.. “The Role of Non-Coding RNAs in the Pathogenesis and Progression of Diabetic Kidney Disease.” International journal of molecular sciences (2026). PMID: 41828573 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup
  115. [115]

    Rhee CM, Zisman-Ilani Y, Kalantar-Zadeh K et al.. “Continuous glucose monitoring in patients with chronic kidney disease on dialysis and with kidney transplantation.” Current opinion in nephrology and hypertension (2026). PMID: 41787610 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Supportive Care and Complication Management
  116. [116]

    Li Y, Yun D, Kwak SH et al.. “Urinary metabolomics identifies isoleucine as a prognostic biomarker for progression of diabetic kidney disease.” Frontiers in endocrinology (2026). PMID: 41948556 ↗

    L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations
  117. [117]

    Lu L, Gu Q, Zheng Y et al.. “Incremental peritoneal dialysis preserves residual renal function in diabetic end-stage kidney disease.” Renal failure (2026). PMID: 41914033 ↗

    L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations
  118. [118]

    Wang Y, Chen W, Xiong X et al.. “Plasma R-spondin 2 levels are associated with the progression of diabetic kidney disease.” Frontiers in endocrinology (2026). PMID: 41907558 ↗

    L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes, Special Populations
  119. [119]

    Wong K, Pitcher D, Barratt J et al.. “Association of UACR and UPCR with kidney failure: analysis of observational data in patients with rare kidney diseases.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 41894233 ↗

    L5OTHERCited in: Diagnosis and Workup
  120. [120]

    Jiang T, Deng J, Hu X et al.. “Integrated multi-omics analysis unveils microbiota-metabolite-host interactions and novel biomarkers for early diabetic kidney disease diagnosis.” Frontiers in immunology (2026). PMID: 41878445 ↗

    L5OTHERCited in: Diagnosis and Workup, Special Populations
  121. [121]

    Li L, Ma F, Bao C et al.. “Development and validation of a multivariable prediction model for non-invasive discrimination between diabetic and non-diabetic kidney disease in type 2 diabetes: a clinical nomogram.” Frontiers in endocrinology (2026). PMID: 41869042 ↗

    L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Prognosis and Long-term Outcomes, Special Populations
  122. [122]

    Mourya B, Sangha SS, Kumar A et al.. “Effect of intravitreal bevacizumab on kidney function and proteinuria among diabetic patients: a prospective observational study in Asian population.” Renal failure (2026). PMID: 41851996 ↗

    L5OTHERCited in: Diagnosis and Workup, Special Populations
  123. [123]

    Li Y, Qin Z, Si T et al.. “Correlation between serum prolactin and the systemic immune-inflammation index in diabetic kidney disease: a cross-sectional study.” Frontiers in endocrinology (2026). PMID: 41847444 ↗

    L5OTHERCited in: Diagnosis and Workup, Special Populations
  124. [124]

    de la Rambelje MA, Beldhuis IE, Heerspink HJL et al.. “Protein profiles and associated biological pathways among different aetiologies of chronic kidney disease: new insights from DAPA-CKD.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 40920470 ↗

    L1bRCTCited in: Differential Diagnosis, Landmark Trials and Key Evidence
  125. [125]

    Garmaa G, Nagy R, Kói T et al.. “Panel miRNAs are potential diagnostic markers for chronic kidney diseases: a systematic review and meta-analysis.” BMC nephrology (2024). PMID: 39138396 ↗

    L2aSR_OBSCited in: Differential Diagnosis
  126. [126]

    Zhao Y, Liu L, Zuo L et al.. “A Novel Risk Score Model for the Differential Diagnosis of Type 2 Diabetic Nephropathy: A Multicenter Study.” Journal of diabetes research (2023). PMID: 38155834 ↗

    L1bRCTCited in: Differential Diagnosis
  127. [127]

    Wang W, Guo W, Xu X et al.. “A rare case of sero-negative anti-glomerular basement membrane disease combined with diabetic nephropathy and literature review.” Renal failure (2025). PMID: 40785208 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  128. [128]

    Wang X, Chen L, Shi K et al.. “Diabetes and chronic kidney disease in Chinese adults: a population-based cohort study.” BMJ open diabetes research & care (2024). PMID: 38267203 ↗

    L2bCOHORTCited in: Differential Diagnosis
  129. [129]

    Hustrini NM, Susalit E, Widjaja FF et al.. “The Etiology of Advanced Chronic Kidney Disease in Southeast Asia: A Meta-analysis.” Journal of epidemiology and global health (2024). PMID: 38587764 ↗

    L2aSR_OBSCited in: Differential Diagnosis
  130. [130]

    Patel CA, Patel S, Patel S et al.. “Targeting TRPC6 in podocytopathies: Why clinical translation remains a challenge?” Pharmacological reports : PR (2026). PMID: 40719843 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  131. [131]

    Lee-Boey JS, Tan JK, Lim ZF et al.. “Obesity-related glomerulopathy: How it happens and future perspectives.” Diabetic medicine : a journal of the British Diabetic Association (2025). PMID: 40226862 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  132. [132]

    Zachariah T, Radhakrishnan J. “Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease.” Clinical journal of the American Society of Nephrology : CJASN (2024). PMID: 39037799 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  133. [133]

    Liu Y, Xu K, Xiang Y et al.. “Role of MCP-1 as an inflammatory biomarker in nephropathy.” Frontiers in immunology (2023). PMID: 38239353 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  134. [134]

    Zhan HQ, Zhang X, Chen XL et al.. “Application of nanotechnology in the treatment of glomerulonephritis: current status and future perspectives.” Journal of nanobiotechnology (2024). PMID: 38169389 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  135. [135]

    Weerasooriya L, Howie AJ, Wakeman MP et al.. “Kidney biopsy findings in children with diabetes mellitus.” Pediatric nephrology (Berlin, Germany) (2024). PMID: 38123711 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  136. [136]

    Juha M, Molnár A, Jakus Z et al.. “NETosis: an emerging therapeutic target in renal diseases.” Frontiers in immunology (2023). PMID: 37744367 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  137. [137]

    Oshima Y, Sawa N, Yamanouchi M et al.. “Clinicopathological cohort study of kidney biopsy findings resulting in dialysis during long-term follow-up exceeding 30 years.” Clinical and experimental nephrology (2025). PMID: 40434507 ↗

    L2bCOHORTCited in: Differential Diagnosis
  138. [138]

    Shaheen M, Bharat A, Friedman AN et al.. “ALECT2 amyloidosis with concurrent IgG4-related interstitial nephritis, membranous nephropathy and diabetic kidney disease: a case report and literature review.” Journal of nephrology (2024). PMID: 38630340 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  139. [139]

    Hu J, Liang Y, Sun K et al.. “Diabetes mellitus with anti-glomerular basement membrane disease and anti-tubular basement membrane disease: a rare case report of reversible dialysis dependence.” Frontiers in immunology (2025). PMID: 41601656 ↗

    L4CASE_REPORTCited in: Differential Diagnosis, Supportive Care and Complication Management
  140. [140]

    Chen G, Wang Y, Zhang L et al.. “Research progress on miR-124-3p in the field of kidney disease.” BMC nephrology (2024). PMID: 39112935 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  141. [141]

    Dybiec J, Frąk W, Kućmierz J et al.. “Liquid Biopsy: A New Avenue for the Diagnosis of Kidney Disease: Diabetic Kidney Disease, Renal Cancer, and IgA Nephropathy.” Genes (2024). PMID: 38254967 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  142. [142]

    Li Z, Han Y, Yuan S et al.. “Clinicopathological characteristics and outcomes in patients with diabetic nephropathy coexisting idiopathic membranous nephropathy: a retrospective observational study.” Renal failure (2026). PMID: 41820026 ↗

    L5OTHERCited in: Differential Diagnosis
  143. [143]

    Zhang H, Lou K, Qian L et al.. “CKAP4 in Extracellular Vesicle-Derived From Podocyte Serves as a Non-Invasive Diagnostic Biomarker for Diabetic Nephropathy and Promotes Vascular Calcification.” Journal of extracellular vesicles (2025). PMID: 41316993 ↗

    L5OTHERCited in: Differential Diagnosis
  144. [144]

    Lin L, Yan L, Li N et al.. “Reliable biomarkers for diabetic nephropathy using machine learning-assisted contrast-enhanced ultrasonography and clinical characteristics.” Clinical and experimental medicine (2025). PMID: 41171478 ↗

    L5OTHERCited in: Differential Diagnosis
  145. [145]

    Yang X, Tang W, Chan H et al.. “Genetic evidence for repurposing GLP-1 receptor agonists in chronic kidney disease and IgA nephropathy: Metabolic and anti-inflammatory pathways beyond glycaemic control.” Diabetes, obesity & metabolism (2025). PMID: 40994081 ↗

    L5OTHERCited in: Differential Diagnosis
  146. [146]

    Conserva F, Pesce F, Cinefra C et al.. “A renal biopsy-anchored multi-marker signature involving AOPEP SNP-driven splicing, miR-27b-3p and glycated albumin for stratifying renal damage in type 2 diabetes.” Diabetes research and clinical practice (2025). PMID: 40934963 ↗

    L5OTHERCited in: Differential Diagnosis
  147. [147]

    Mu F, Bai X, Bai X et al.. “Analysis of pathological spectrum characteristics in elderly patients with nephrotic syndrome: a comparative study with non-elderly patients.” Renal failure (2025). PMID: 40803348 ↗

    L5OTHERCited in: Differential Diagnosis
  148. [148]

    Wu M, Zhou X, Chen S et al.. “The alternations of gut microbiota in diabetic kidney disease: insights from a triple comparative cohort.” Frontiers in cellular and infection microbiology (2025). PMID: 40654567 ↗

    L5OTHERCited in: Differential Diagnosis
  149. [149]

    Yin T, Yang L, Tang L et al.. “Podocyte FFAR4 deficiency aggravated glomerular diseases and aging.” Molecular therapy : the journal of the American Society of Gene Therapy (2025). PMID: 40450519 ↗

    L5OTHERCited in: Differential Diagnosis
  150. [150]

    Abe M, Niioka H, Matsumoto A et al.. “Self-Supervised Learning for Feature Extraction from Glomerular Images and Disease Classification with Minimal Annotations.” Journal of the American Society of Nephrology : JASN (2025). PMID: 40029749 ↗

    L5OTHERCited in: Differential Diagnosis
  151. [151]

    Kitamura H, Tanaka S, Hiyamuta H et al.. “Associations of Causes of Chronic Kidney Disease with Disease Progression and Mortality: Insights from the Fukuoka Kidney Disease Registry Study.” American journal of nephrology (2025). PMID: 39778545 ↗

    L5OTHERCited in: Differential Diagnosis
  152. [152]

    Fountoulakis N, Pavlou P, Stathi D et al.. “Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.” Diabetes, obesity & metabolism (2026). PMID: 41705420 ↗

    L1bRCTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations
  153. [153]

    Wexler DJ, Mayberry LS, Nelson LA et al.. “Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial.” American heart journal (2026). PMID: 41456635 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  154. [154]

    Lado-Abeal J, Gude F, Ginzo-Villamayor MJ et al.. “Impact of specialised endocrinology care on metabolic control and healthcare utilisation outcomes after kidney transplantation in patients with diabetes: A 12-month observational cohort study.” Diabetes, obesity & metabolism (2026). PMID: 41725429 ↗

    L2bCOHORTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations
  155. [155]

    Cao Y, Li S, Li X et al.. “Association Between Diabetes-Related Lower-Extremity Amputations and Renal Function: An Observational, Single-Center, Retrospective Cohort Study.” The Journal of surgical research (2026). PMID: 41349163 ↗

    L2bCOHORTCited in: Supportive Care and Complication Management
  156. [156]

    Erzeel J, van Es M, Mullens W et al.. “Evolving Mineralocorticoid Receptor Antagonism: a Narrative Review on Differences between Steroidal MRAs, Non-Steroidal MRAs and Aldosterone Synthase Inhibitors in Cardiorenal Disease.” Current heart failure reports (2026). PMID: 41615644 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  157. [157]

    Ntelis S, Wojeck BS. “Obesity Medications Beyond Glucose Control and Weight Reduction: Updates on the Expanding Benefits, Clinical Challenges, and Future Directions.” Current hypertension reports (2025). PMID: 41460420 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  158. [158]

    Wang Y, Zhang Y, Jin Q et al.. “The role of mitochondrial-associated endoplasmic reticulum membranes (MAMs) in diabetic microvascular complications: a review.” Cell death & disease (2025). PMID: 41366202 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  159. [159]

    Rykova E, Shmakova E, Damarov I et al.. “Non-Coding RNA in Type 2 Diabetes Cardio-Renal Complications and SGLT2 Inhibitor Response.” International journal of molecular sciences (2025). PMID: 41303682 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  160. [160]

    Chen ZH, Li D, Zhang JY et al.. “SUMOylation and NEDDylation in kidney diseases.” Experimental and molecular pathology (2025). PMID: 41273879 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  161. [161]

    Yuan D, Vangaveti VN, Arojojoye OA et al.. “Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus: A Retrospective Study.” Journal of diabetes research (2025). PMID: 41246137 ↗

    L2bCOHORTCited in: Supportive Care and Complication Management
  162. [162]

    Murata A, Tanaka M, Takayoshi M et al.. “Osmotic nephropathy as a potentially underrecognized cause of acute kidney injury during SGLT2 inhibitor therapy: a case report and literature review.” CEN case reports (2026). PMID: 41501207 ↗

    L4CASE_REPORTCited in: Supportive Care and Complication Management
  163. [163]

    Raza SA, Rehman AU, Aamir AH et al.. “Comparative efficacy and safety of finerenone in diabetic kidney disease: a meta-analysis of Asian and non-Asian populations.” BMC nephrology (2025). PMID: 41272492 ↗

    L2aSR_OBSCited in: Prognosis and Long-term Outcomes
  164. [164]

    Ma J, Su Q, Wang H et al.. “Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study.” Drug design, development and therapy (2026). PMID: 41878680 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes
  165. [165]

    Tsai HJ, Yu PS, Hung WW et al.. “Trajectories of short-chain fatty acids and risk of adverse kidney outcomes in type 2 diabetes: a prospective cohort study.” Postgraduate medicine (2026). PMID: 41789569 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes
  166. [166]

    Yu Y, Yu J, Li J et al.. “The Prognostic Nutritional Index and Glycemic Status Synergistically Predict Early Renal Function Decline in Type 2 Diabetes: A Community-Based Cohort Study.” Nutrients (2026). PMID: 41683219 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes
  167. [167]

    Li L, Bao J, Zheng Y et al.. “Effect of Luteolin Supplementation on Kidney Damage and Long-Term Prognosis in Diabetic Patients: A Cohort Study.” Phytotherapy research : PTR (2026). PMID: 41493853 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes
  168. [168]

    Liu Y, Hu X, Jia J. “Adjunctive nutritional intervention improves glycaemia and quality of life in dapagliflozin-treated diabetic patients.” Pakistan journal of pharmaceutical sciences (2026). PMID: 41482798 ↗

    L1bRCTCited in: Prognosis and Long-term Outcomes
  169. [169]

    Han Y, Mao R, Xiong C et al.. “Development and external validation of a machine learning model for predicting in-hospital mortality in ICU patients with diabetic kidney disease: a study utilizing the MIMIC database and a Chinese cohort.” Frontiers in endocrinology (2026). PMID: 41837124 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes, Special Populations
  170. [170]

    Moedt E, Coca SG, Edwards K et al.. “Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials.” Diabetes care (2026). PMID: 41217780 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence, Guidelines and Resources
  171. [171]

    Januzzi JLJ, Sattar N, Vaduganathan M et al.. “A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease.” Cardiovascular diabetology (2025). PMID: 40375260 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  172. [172]

    Li P, Zheng H, Ma J et al.. “Impact of finerenone on chronic kidney disease progression in Chinese patients with type 2 diabetes: a FIGARO-DKD subgroup analysis.” Frontiers in endocrinology (2025). PMID: 40370775 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  173. [173]

    Beal B, Buizen L, Yeung EK et al.. “Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025). PMID: 40036884 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  174. [174]

    Siriwardana A, Buizen L, Jun M et al.. “Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial.” Diabetes, obesity & metabolism (2025). PMID: 39781601 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  175. [175]

    Ferrannini E, Baldi S, Scozzaro MT et al.. “Fasting substrates predict chronic kidney disease progression in CREDENCE trial patients with type 2 diabetes.” JCI insight (2024). PMID: 39704168 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  176. [176]

    de Vries ST, Pena MJ, Tye SC et al.. “Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials.” Diabetologia (2025). PMID: 39656268 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  177. [177]

    Mahaffey KW, Tuttle KR, Arici M et al.. “Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.” European heart journal (2025). PMID: 39211948 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence, Guidelines and Resources
  178. [178]

    Cardoza K, Kang A, Smyth B et al.. “Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.” Diabetes, obesity & metabolism (2024). PMID: 38895796 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  179. [179]

    McEwan P, Gabb PD, Davis JA et al.. “The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 38730538 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  180. [180]

    Januzzi JL, Liu Y, Sattar N et al.. “Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.” American heart journal (2024). PMID: 38401646 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  181. [181]

    . “Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.” The lancet. Diabetes & endocrinology (2024). PMID: 38061372 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  182. [182]

    Eissing T, Goulooze SC, van den Berg P et al.. “Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.” Diabetes, obesity & metabolism (2024). PMID: 38037539 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  183. [183]

    Koya D, Anker SD, Ruilope LM et al.. “Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.” American journal of nephrology (2023). PMID: 37708857 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  184. [184]

    Mohebi R, Liu Y, Hansen MK et al.. “Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial.” Cardiovascular diabetology (2023). PMID: 37438734 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  185. [185]

    van der Hoek S, Jongs N, Oshima M et al.. “Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 36999981 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  186. [186]

    Sarafidis P, Agarwal R, Pitt B et al.. “Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.” Clinical journal of the American Society of Nephrology : CJASN (2023). PMID: 36927680 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  187. [187]

    Yi TW, Smyth B, Di Tanna GL et al.. “Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 36889425 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  188. [188]

    Bramlage P, Lanzinger S, Mühldorfer S et al.. “An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria.” Cardiovascular diabetology (2023). PMID: 37158855 ↗

    L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence
  189. [189]

    Dai ZC, Chen JX, Zou R et al.. “Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.” Frontiers in immunology (2023). PMID: 37809091 ↗

    L2aSR_OBSCited in: Landmark Trials and Key Evidence
  190. [190]

    Delanaye P, Scheen AJ. “[EMPA-KIDNEY: empagliflozin in chronic kidney disease].” Revue medicale de Liege (2023). PMID: 36634063 ↗

    L1bRCTCited in: Landmark Trials and Key Evidence
  191. [191]

    Schaefer F, Montini G, Kang HG et al.. “Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.” Trials (2024). PMID: 38509517 ↗

    L2bTRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence
  192. [192]

    Yi TW, Atiquzzaman M, Zheng Y et al.. “Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study.” Canadian journal of kidney health and disease (2022). PMID: 36578697 ↗

    L2bCOHORTCited in: Landmark Trials and Key Evidence
  193. [193]

    Neuen BL, Heerspink HJL, Vart P et al.. “Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.” Circulation (2024). PMID: 37952217 ↗

    L4CASE_REPORTCited in: Landmark Trials and Key Evidence
  194. [194]

    Moedt E, Ju W, Nair V et al.. “Novel protein biomarkers for risk stratification and personalized medicine.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 41874429 ↗

    L5OTHERCited in: Landmark Trials and Key Evidence
  195. [195]

    Rayner B, Mahaffey KW, Mann JFE et al.. “Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 41728915 ↗

    L5OTHERCited in: Landmark Trials and Key Evidence
  196. [196]

    Mir R, Elfaki I, Almassabi RF et al.. “Identification of novel genomic variants in diabetic nephropathy patients using whole-exome sequencing: a pilot investigation.” Frontiers in endocrinology (2026). PMID: 41970998 ↗

    L5OTHERCited in: Special Populations
  197. [197]

    Yang S, Liu S, Ma Y et al.. “Real-world performance of open-source large language models in diabetes diagnosis.” Frontiers in endocrinology (2026). PMID: 41958877 ↗

    L5OTHERCited in: Special Populations
  198. [198]

    Adamczak M, Kurnatowska I, Naumnik B et al.. “Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus-Clinical Practice Position Statement of the Polish Society of Nephrology.” International journal of molecular sciences (2024). PMID: 39684653 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  199. [199]

    Dasgupta I, Zac-Varghese S, Chaudhry K et al.. “Current management of chronic kidney disease in type-2 diabetes-A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) guidelines.” Diabetic medicine : a journal of the British Diabetic Association (2025). PMID: 39415639 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  200. [200]

    Zac-Varghese S, Mark P, Bain S et al.. “Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024.” BMC nephrology (2024). PMID: 38971750 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  201. [201]

    Sugawara Y, Kanda E, Hamano T et al.. “Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices.” Clinical and experimental nephrology (2024). PMID: 38970650 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  202. [202]

    Almatham KI, Almudaiheem HY, Alhazzani WA et al.. “Saudi Clinical Practice Guidelines for management of diabetic kidney disease in adults.” Saudi medical journal (2025). PMID: 41087076 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  203. [203]

    Montero N, Oliveras L, Martínez-Castelao A et al.. “Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology.” Nefrologia (2025). PMID: 40222774 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  204. [204]

    Mosenzon O, Raz I, Wiviott SD et al.. “Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.” Diabetes care (2022). PMID: 35997319 ↗

    L1bRCTCited in: Guidelines and Resources
  205. [205]

    Spasovski G, Markovska ZS, Gjorgjievski N et al.. “Diabetic Kidney Disease Position Paper of the Macedonian Society of Nephrology, Dialysis, Transplantation and Artificial Organs (MSNDTAO), Macedonian Society of Cardiology (MSC), and Scientific Association of Endocrinologists and Diabetologists of Macedonia (SAEDM).” Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki) (2024). PMID: 39667008 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  206. [206]

    . “[National technical guidelines for the prevention and treatment of diabetic kidney disease in primary care (2023)].” Zhonghua nei ke za zhi (2023). PMID: 38044065 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  207. [207]

    Xu X, Zhao X, Ding Y et al.. “Effects of Intensive Systolic Blood Pressure Control on Kidney Outcomes in Patients With and Without CKD: A Post Hoc Analysis of SPRINT and ACCORD-BP Trials.” Journal of diabetes (2025). PMID: 41117098 ↗

    L1bRCTCited in: Guidelines and Resources
  208. [208]

    Thiab S, Akhal T, Akeblersane M et al.. “Microvascular complications in prediabetes: a systematic review & meta-analysis.” Diabetes research and clinical practice (2025). PMID: 40419194 ↗

    L2aSR_OBSCited in: Guidelines and Resources
  209. [209]

    Makvandi K, Eliasson B, Carlsen HK et al.. “Burden and Excess Risk of Adverse Outcomes in Patients With Type 1 Diabetes Using KDIGO Classification: A National Cohort Study.” Diabetes care (2025). PMID: 39565836 ↗

    L2bCOHORTCited in: Guidelines and Resources
  210. [210]

    Plattner C, Sallaberger S, Bohn JP et al.. “Rationale and design of the Innsbruck Diabetic Kidney Disease Cohort (IDKDC)-a prospective study investigating etiology and progression of early-stage chronic kidney disease in type 2 diabetes.” Clinical kidney journal (2024). PMID: 38726211 ↗

    L2bCOHORTCited in: Guidelines and Resources
  211. [211]

    Nicholas SB, Correa-Rotter R, Desai NR et al.. “First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting.” Journal of nephrology (2024). PMID: 39340711 ↗

    L2bTRIAL_NONRANDOMCited in: Guidelines and Resources
  212. [212]

    Zhang Y, Singh P, Ganapathy K et al.. “Efficacy of continuous glucose monitoring in people living with diabetes and end stage kidney disease on dialysis: a systematic review.” BMC nephrology (2024). PMID: 39455937 ↗

    L2aSR_OBSCited in: Guidelines and Resources
  213. [213]

    Levin-Iaina N, El'Nasasra H, Reiner-Benaim A. “Real-world implementation of the 2020 KDIGO guidelines for diabetes management in chronic kidney disease: a single-center retrospective study.” Frontiers in nephrology (2025). PMID: 41031090 ↗

    L2bCOHORTCited in: Guidelines and Resources
  214. [214]

    . “11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026.” Diabetes care (2026). PMID: 41358881 ↗

    L5REVIEW_NARRATIVECited in: Guidelines and Resources
  215. [215]

    Guarino S, Iafusco D, Di Sessa A et al.. “Acidosis at Diagnosis of Type 1 Diabetes Mellitus: Relation With Kidney Function.” Pediatric diabetes (2025). PMID: 41293549 ↗

    L5OTHERCited in: Guidelines and Resources
  216. [216]

    Fernandez-Fernandez B, Hasegawa T, Saruta Y et al.. “Plasma Interleukin 22 Predicts Progression of Early Diabetic Kidney Disease.” American journal of nephrology (2025). PMID: 40920595 ↗

    L5OTHERCited in: Guidelines and Resources
  217. [217]

    Driendl S, Stadler S, Baumert M et al.. “Nocturnal hypoxemic burden is associated with worsening prognosis of chronic kidney disease in patients with type 2 diabetes.” Cardiovascular diabetology (2025). PMID: 40887593 ↗

    L5OTHERCited in: Guidelines and Resources
  218. [218]

    Kalhan TA, Luo M, Chai JH et al.. “Health economic evaluation of a risk-stratified intervention in diabetic kidney disease.” Diabetologia (2025). PMID: 40739365 ↗

    L5OTHERCited in: Guidelines and Resources
  219. [219]

    Melsom T, Brobak KM, Norvik JV et al.. “Iohexol clearance, but not estimated GFR, reveals a steeper GFR decline in patients with prediabetes.” Kidney international (2025). PMID: 40645290 ↗

    L5OTHERCited in: Guidelines and Resources
  220. [220]

    Mohamed S, Lipscombe LL, Lipscombe J et al.. “Prevalence of diabetic kidney disease by world region of birth among immigrants and long-term residents of Canada with type 2 diabetes.” Diabetes research and clinical practice (2025). PMID: 40639770 ↗

    L5OTHERCited in: Guidelines and Resources
  221. [221]

    Wanner C, Zhao MH, Amin AN et al.. “Guideline-Recommended Disease-Modifying Therapies for Patients with Cardiorenal Disease: A Call-to-Action Narrative Review.” Advances in therapy (2025). PMID: 40434618 ↗

    L5REVIEW_NARRATIVECited in: Guidelines and Resources

Revision History

All updates applied to this page

Loading revisions…